Quick Take

Praxis Precision Medicines (PRAX) has filed to raise $126 million in an IPO of its common stock, according to an S-1 registration statement.

The firm is developing drug treatment candidates for central nervous system disorders.

PRAX has produced intriguing early efficacy results for its lead candidate and the IPO, while not cheap, is worth consideration.

Company & Technology

Cambridge, Massachusetts-based Praxis was founded to advance a pipeline of treatments for both broad psychiatric-related and rare diseases of the central nervous system having to do with neuronal imbalances.

Management is headed by president and Chief Executive Officer Mr. Marcio Souza, who has been with the firm since April 2020 and was previously Chief Operating Officer at PTC Therapeutics.

Below is a brief overview video of symptoms of major depressive disorder:

Source: Psych Hub Education

The company’s lead candidate, PRAX-114, is being developed to treat major depressive disorder as both

Read More

Over dependence on one country, China, for basic ingredients required to make medicines is a cause for concern, observed Justice N Kirubakaran of the Madras High Court.

India has emerged as a pioneer in pharmaceuticals. Yet, for the basic ingredients of medicine-making, it is heavily dependent on imports from one single neighbour nation – China. “This dependency handicaps us in responding effectively to security and other breaches by the neighbour. It also makes our patients to more often contend with spurious and sub-standard drugs and placing them in a vulnerable prospect of going without medicines if tensions escalate between the two countries, especially after Galwan valley tussle,” he said.

The Judge’s observations in his 226-page judgment was passed on a couple of writ petitions filed in 2017 by the city-based Vinkem Labs. The company that manufacturers medicines to treat cancer complained about lack of government support in carrying out generic

Read More

PRINCETON, N.J., Oct. 1, 2020 /PRNewswire/ — Sandoz Inc announced today that its first two injectable medicines with Radio Frequency Identification (RFID) tags will be available this month to US hospitals through its collaboration with Kit Check, Inc., a leader in automated medication management solutions for hospitals.

The first two medicines include Anectine 200 mg/10mL and Rocuronium 50mg/5mL and 10mg/5mL (paralytics to relax muscles during surgery or other medical procedures). Several more Sandoz medicines are expected to be made available to Kit Check’s hospital partners through early 2021.

“Maintaining inventory of critical medicines is vital for hospitals to effectively treat patients, especially during COVID-19. Several products included in our collaboration with Kit Check are important hospital medicines that physicians rely on for immediate treatment of critically ill patients,” said Carol Lynch, President of Sandoz, Inc. “This aligns with our strategy to supplement our ongoing work through disruptive channels to ensure

Read More